Leiden

• Dose-finding and safety study of a new Shigella vaccine combined with an adjuvant in the Netherlands and Zambia Ended
  2023-506394-35-02 3 2024-09-12 Vaccination against shigellosis (in healthy adults)
• YF_PROTECT: Prophylactic treatment with sofosbuvir for Yellow Fever Ended
  2024-510949-34-00 6 2024-09-11 Healthy volunteers
• A study on the effects of a new drug on the sensitivity of the nerves in healthy volunteers Ended
  2024-515390-99-00 3 2024-09-06 Hyperexcitability nerve disorder
• Repeated corticosteroid injections around the Greater Occipital Nerve (GON) as prophylactic treatment in chronic cluster headache Ended
  2024-514311-10-00 5 2024-08-10 Cluster headache
• A study to investigate immune challenge induced skin reactions with SAR445399, canakinumab and spesolimab compared with placebo, in healthy … Ended
  2024-511241-19-00 3 2024-07-19 Immuun system diseases
• Single Ascending Dose study of ENX-104 Ended
  2024-514265-19-00 1 2024-07-17 Major Depressive Disorder
• Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants Ended
  2024-511618-19-00 3 2024-06-24 Immune system diseases
• Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic … Ended
  2022-503009-39-00 3 2024-06-04 Subacute Cutaneous Lupus Erythematosus
• Intradermal LPS to study vascular responses Ended
  2024-512377-27-00 3 2024-05-28 Immunological/cardiovascular conditions
• LIBERAL Study Ended
  2023-507823-52-00 5 2024-05-27 Patients with chronic kidney disease stage 3b to 4
• A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations Ended
  2022-502595-23-00 7 2024-05-21 Patients with locally advanced or metastatic non-small cell lung cance
• A Randomized, double-blind, placebo-controlled, three-way cross-over study to assess the pharmacodynamic effects of an authorised and a new … Ended
  2024-510721-26-00 3 2024-05-17 neuropathic pain
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1117570 in Healthy Adults Ended
  2023-508814-40-00 3 2024-03-11 Neurological and neuropsychiatric conditions
• The effect of fentanyl on breathing Ended
  2023-508915-22-00 5 2024-03-04 none, healthy subjects
• This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu … Ended
  2023-504800-28-00 3 2024-02-23 Chronic Inducible Urticaria
• This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu … Ended
  2023-504799-94-00 4 2024-02-20 Chronic Spontaneous Urticaria
• A controlled human rhinovirus infection study of 2-Deoxy-D-Glucose in healthy adults. Ended
  2023-509311-91-01 4 2024-02-15 Rhinovirus-associated illness
• Feasibility and tolerability of 28 days intravaginal oxybutynin via the MedRing OAB system Ended
  2023-508692-36-00 3 2024-02-06 Overactive bladder
• Safety, tolerability, pharmacokinetics and pharmacodynamics of ARV-102 in healthy participants Ended
  2023-507910-28-00 1 2024-01-04 Parkinson's Disease
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• CBD, amitriptyline and tramadol drug-drug interaction study Ended
  2023-508428-36-00 4 2023-12-19 Neurological assessments
• Imatinib PD in healthy subjects Ended
  2023-504958-35-00 3 2023-12-13 Immuno-oncology assessments
• Focus Green: Fluorescence-guided resection Of Colorectal liver metastases Using SGM-101 and Indocyanine GREEN Ended
  2023-504615-33-00 4 2023-12-12 colorectal livermetastases
• FLUOPANC II: A performance study of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody for fluorescence-guide … Ended
  2023-510481-27-00 4 2023-12-11 Pancreatic tumor

Showing 361–384 of 450 trials